Cxbladder is a suite of non-invasive genomic tests designed to help rule out urothelial bladder cancer in patients being monitored for recurrent non-muscle invasive disease and in those presenting with hematuria (blood in urine).
The test uses urine-based sampling, including the option of in-home collection, to analyze biomarker genes and provide accurate risk stratification. Cxbladder aims to reduce the need for invasive procedures in patients at low risk of disease, improving patient comfort and clinical efficiency.
Supported by over 30 peer-reviewed publications, Cxbladder Triage is included in the AUA/SUFU Microhematuria Guideline, reflecting its clinical validity and utility in modern urological practice.